223 related articles for article (PubMed ID: 19576971)
1. Investigations on the human hepatic cytochrome P450 isozymes involved in the metabolism of 3,4-methylenedioxy-amphetamine (MDA) and benzodioxolyl-butanamine (BDB) enantiomers.
Meyer MR; Peters FT; Maurer HH
Toxicol Lett; 2009 Oct; 190(1):54-60. PubMed ID: 19576971
[TBL] [Abstract][Full Text] [Related]
2. Stereoselective differences in the cytochrome P450-dependent dealkylation and demethylenation of N-methyl-benzodioxolyl-butanamine (MBDB, Eden) enantiomers.
Meyer MR; Peters FT; Maurer HH
Biochem Pharmacol; 2009 Jun; 77(11):1725-34. PubMed ID: 19428327
[TBL] [Abstract][Full Text] [Related]
3. The role of human hepatic cytochrome P450 isozymes in the metabolism of racemic 3,4-methylenedioxy-methamphetamine and its enantiomers.
Meyer MR; Peters FT; Maurer HH
Drug Metab Dispos; 2008 Nov; 36(11):2345-54. PubMed ID: 18725511
[TBL] [Abstract][Full Text] [Related]
4. The role of human hepatic cytochrome P450 isozymes in the metabolism of racemic 3,4-methylenedioxyethylamphetamine and its single enantiomers.
Meyer MR; Peters FT; Maurer HH
Drug Metab Dispos; 2009 Jun; 37(6):1152-6. PubMed ID: 19299523
[TBL] [Abstract][Full Text] [Related]
5. Enantioselectivity in the methylation of the catecholic phase I metabolites of methylenedioxy designer drugs and their capability to inhibit catechol-O-methyltransferase-catalyzed dopamine 3-methylation.
Meyer MR; Maurer HH
Chem Res Toxicol; 2009 Jun; 22(6):1205-11. PubMed ID: 19462939
[TBL] [Abstract][Full Text] [Related]
6. Participation of cytochrome P450-2B and -2D isozymes in the demethylenation of methylenedioxymethamphetamine enantiomers by rats.
Kumagai Y; Lin LY; Hiratsuka A; Narimatsu S; Suzuki T; Yamada H; Oguri K; Yoshimura H; Cho AK
Mol Pharmacol; 1994 Feb; 45(2):359-65. PubMed ID: 7906857
[TBL] [Abstract][Full Text] [Related]
7. Regiochemical differences in cytochrome P450 isozymes responsible for the oxidation of methylenedioxyphenyl groups by rabbit liver.
Kumagai Y; Lin LY; Philpot RM; Yamada H; Oguri K; Yoshimura H; Cho AK
Mol Pharmacol; 1992 Oct; 42(4):695-702. PubMed ID: 1435745
[TBL] [Abstract][Full Text] [Related]
8. Enantiomer analysis of a new street drug, 3,4-methylenedioxy-N-methyl-butanamine, in rat urine.
Nagai T; Matsushima K; Suzuki A; Saotome A; Kurosu A; Nihei H; Kuroyanagi K; Tokudome S
J Anal Toxicol; 2002 Mar; 26(2):104-9. PubMed ID: 11916012
[TBL] [Abstract][Full Text] [Related]
9. Metabolism of methylenedioxyphenyl compounds by rabbit liver preparations. Participation of different cytochrome P450 isozymes in the demethylenation reaction.
Kumagai Y; Wickham KA; Schmitz DA; Cho AK
Biochem Pharmacol; 1991 Aug; 42(5):1061-7. PubMed ID: 1678603
[TBL] [Abstract][Full Text] [Related]
10. [Mass spectrometry data of some metabolites of the amphetamine derivatives 3,4-(methylenedioxy) amphetamine (MDA) and 3,4-methylenedioxy)methylamphetamine (MDMA)].
Verweij AM
Arch Kriminol; 1996; 197(1-2):27-30. PubMed ID: 8851250
[TBL] [Abstract][Full Text] [Related]
11. Adam and Eve make love. Analysis of the enantiomers of 3,4-methylenedioxy-N-ethylamphetamine (MDE, "Eve") and its metabolite 3,4-methylenedioxyamphetamine (MDA) in rat brain.
Tucker G
Hum Exp Toxicol; 1996 May; 15(5):455-7. PubMed ID: 8735473
[No Abstract] [Full Text] [Related]
12. CYP2B6, CYP2D6, and CYP3A4 catalyze the primary oxidative metabolism of perhexiline enantiomers by human liver microsomes.
Davies BJ; Coller JK; Somogyi AA; Milne RW; Sallustio BC
Drug Metab Dispos; 2007 Jan; 35(1):128-38. PubMed ID: 17050648
[TBL] [Abstract][Full Text] [Related]
13. Stereochemical differences in the metabolism of 3,4-methylenedioxymethamphetamine in vivo and in vitro: a pharmacokinetic analysis.
Cho AK; Hiramatsu M; Distefano EW; Chang AS; Jenden DJ
Drug Metab Dispos; 1990; 18(5):686-91. PubMed ID: 1981721
[TBL] [Abstract][Full Text] [Related]
14. Identification of N-methyl-1-(3,4-methylenedioxyphenyl)-2-butanamine (MBDB) in urine from drug users.
Kronstrand R
J Anal Toxicol; 1996 Oct; 20(6):512-6. PubMed ID: 8889691
[TBL] [Abstract][Full Text] [Related]
15. Enzymatic and chemical demethylenation of (methylenedioxy)amphetamine and (methylenedioxy)methamphetamine by rat brain microsomes.
Lin LY; Kumagai Y; Cho AK
Chem Res Toxicol; 1992; 5(3):401-6. PubMed ID: 1354504
[TBL] [Abstract][Full Text] [Related]
16. The demethylenation of methylenedioxymethamphetamine ("ecstasy") by debrisoquine hydroxylase (CYP2D6).
Tucker GT; Lennard MS; Ellis SW; Woods HF; Cho AK; Lin LY; Hiratsuka A; Schmitz DA; Chu TY
Biochem Pharmacol; 1994 Mar; 47(7):1151-6. PubMed ID: 7909223
[TBL] [Abstract][Full Text] [Related]
17. Stereochemical analysis of 3,4-methylenedioxymethamphetamine and its main metabolites in human samples including the catechol-type metabolite (3,4-dihydroxymethamphetamine).
Pizarro N; Farré M; Pujadas M; Peiró AM; Roset PN; Joglar J; de la Torre R
Drug Metab Dispos; 2004 Sep; 32(9):1001-7. PubMed ID: 15319342
[TBL] [Abstract][Full Text] [Related]
18. Determination of the mechanism of demethylenation of (methylenedioxy)phenyl compounds by cytochrome P450 using deuterium isotope effects.
Fukuto JM; Kumagai Y; Cho AK
J Med Chem; 1991 Sep; 34(9):2871-6. PubMed ID: 1680196
[TBL] [Abstract][Full Text] [Related]
19. Use of MDA (the "love drug") and methamphetamine in Toronto by unsuspecting users of ecstasy (MDMA).
Kalasinsky KS; Hugel J; Kish SJ
J Forensic Sci; 2004 Sep; 49(5):1106-12. PubMed ID: 15461119
[TBL] [Abstract][Full Text] [Related]
20. Identification of the human cytochromes P450 involved in the oxidative metabolism of "Ecstasy"-related designer drugs.
Kreth K; Kovar K; Schwab M; Zanger UM
Biochem Pharmacol; 2000 Jun; 59(12):1563-71. PubMed ID: 10799653
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
